MRNA logo Moderna +
Moderna
+

Moderna (MRNA) Business News

Track Moderna in real time with a live news feed covering Moderna stock news, official press releases, company announcements, and an archive of historical Moderna news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

California Public Employees Retirement System Purchases 149,192 Shares of Moderna, Inc. $MRNA

Defense World

4:17 AM | Wednesday | Jul 22, 2026

news photo
Loading...

California Public Employees Retirement System raised its position in Moderna, Inc. (NASDAQ: MRNA) by 31.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 628,160 shares of the company's stock after purchasing an additional 149,192 shares during the quarter. California Public Employees

Read full article redirect
4:17 AM | Wednesday | Jul 22, 2026

California Public Employees Retirement System Purchases 149,192 Shares of Moderna, Inc. $MRNA

Defense World

California Public Employees Retirement System raised its position in Moderna, Inc. (NASDAQ: MRNA) by 31.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 628,160 shares of the company's stock after purchasing an additional 149,192 shares during the quarter. California Public Employees

Read full article arrow
News Thumbnail
4:17 AM | Wednesday | Jul 22, 2026

California Public Employees Retirement System Purchases 149,192 Shares of Moderna, Inc. $MRNA

Defense World

California Public Employees Retirement System raised its position in Moderna, Inc. (NASDAQ: MRNA) by 31.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 628,160 shares of the company's stock after purchasing an additional 149,192 shares during the quarter. California Public Employees

Read full article arrow
News Thumbnail
8:00 PM | Tuesday | Jul 21, 2026

Should You Buy Moderna Stock Hand Over Fist Before Aug. 5?

The Motley Fool

Moderna is racing towards an important approval. But it may not move the stock higher.

Read full article arrow
News Thumbnail
1:32 PM | Tuesday | Jul 21, 2026

IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?

Fool - Investing News

IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.

Read full article arrow
News Thumbnail
6:51 PM | Monday | Jul 20, 2026

Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights

Zacks Investment Research

In the most recent trading session, Moderna (MRNA) closed at $59.49, indicating a -3.77% shift from the previous trading day.

Read full article arrow
News Thumbnail
6:10 PM | Monday | Jul 20, 2026

Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.

The Motley Fool

Moderna is known as a coronavirus vaccine giant, but it's progressively becoming a multi-product company. The biotech has several exciting candidates in late-stage trials.

Read full article arrow
News Thumbnail
12:01 PM | Friday | Jul 17, 2026

MRNA Advances Cancer Pipeline With New Immunotherapy Study

Zacks Investment Research

Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.

Read full article arrow
News Thumbnail
7:00 AM | Thursday | Jul 16, 2026

Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors

Accesswire

CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. mRNA-4200 encodes for seven antigens commonly shared across patients and tumor types and is designed to help induce and expand T-cell responses against selected tumor targets.

Read full article arrow
News Thumbnail
1:37 PM | Tuesday | Jul 14, 2026

Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies

Proactive Investors

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19 vaccine demand and updates on the company's late-stage pipeline, including anticipated Phase III melanoma data. Jefferies analysts expect a largely uneventful earnings report after Moderna previously guided for second-quarter revenue of $50 million to $100 million, down from $389 million in the first quarter, reflecting the seasonal nature of COVID vaccine sales.

Read full article arrow
News Thumbnail
9:35 AM | Tuesday | Jul 14, 2026

Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies

Proactive Investors - Finance

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19...

Read full article arrow
News Thumbnail
8:00 AM | Monday | Jul 13, 2026

Arbutus Biopharma: Moderna Validates My IP Bull Case

Seeking Alpha

Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusiran has shown durable viral control. The main caveat is that it comes from combo therapies. Their balance sheet gives them a comfortable runway to pursue imdusiran's upcoming Phase 2b trial, which is yet another optionality vertical for the stock.

Read full article arrow
News Thumbnail